Analyst Activity – Deutsche Bank AG Initiates Coverage On TherapeuticsMD (NASDAQ:TXMD) With a Buy

Analyst Ratings For TherapeuticsMD (NASDAQ:TXMD)

Story continues below

Today, Deutsche Bank AG initiated coverage on TherapeuticsMD (NASDAQ:TXMD) with a Buy.

There are 7 buy ratings on the stock.

The current consensus rating on TherapeuticsMD (NASDAQ:TXMD) is Buy (Score: 3.00) with a consensus target price of $17.17 per share, a potential 219.68% upside.

Some recent analyst ratings include

  • 7/21/2017-Deutsche Bank AG initiated coverage with a Buy rating.
  • 7/17/2017-Cowen and Company Reiterated Rating of Outperform.
  • 7/11/2017-CIBC Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 7/11/2017-Oppenheimer Holdings, Inc. Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 5/24/2017-Stifel Nicolaus Reiterated Rating of Buy.
  • 5/10/2017-Cantor Fitzgerald Reiterated Rating of Overweight.

    Recent Trading Activity for TherapeuticsMD (NASDAQ:TXMD)
    Shares of TherapeuticsMD closed the previous trading session at 5.37 up +0.02 0.37% with 2,046,268 shares trading hands.

    An ad to help with our costs